USA-based Madrigal Pharmaceuticals today announced that it has entered into an exclusive global license agreement with CSPC ...

AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical significance for its primary endpoint in AL amyloidosis, although it showed promise ...

For the first target addressed in the partnership, the two companies reported the successful delivery of AI-designed, ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

Madrigal Pharmaceuticals said on Wednesday it has entered into a licensing agreement worth up to $2 billion with China's CSPC Pharmaceutical Group to develop an oral GLP-1 drug for a serious form of ...

U.S. drugmaker Madrigal Pharmaceuticals has struck a licensing deal with CSPC Pharmaceutical Group that could be worth more than $2 billion for the Chinese company if it results in a new drug for a ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

CSPC PHARMA (01093.HK) announced that it had entered into a strategic research collaboration agreement with AstraZeneca for the discovery and development of novel oral small molecu ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

China is being viewed by the biotech and life sciences industry as a threat to US innovation. One pharma CEO thinks it may not be the worst thing to happen to the industry.

AstraZeneca, Pfizer and other multinational drug companies have spent a record amount on medicines developed by Chinese biotechs this year, underscoring how Big Pharma is increasingly reliant on China ...